Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.
